An investigation of the rate of cyclooxygenase-2 expression on the surface of adenomatous and colorectal adenocarcinoma polyps

Baghaei, Ramin; Beiraghdar, Mozhdeh; Sobhani, Ahmad; Rafei, Rahmatolah; Kolahi, Leila; Foladi, Lotfolah

An investigation of the rate of cyclooxygenase-2 expression on the surface of adenomatous and colorectal adenocarcinoma polyps

Authors

¹ Department of Internal Medicine, Arak University of Medical Sciences, Arak, Iran

² Department of Pathology, Isfahan University of Medical Sciences, Isfahan, Iran

³ Department of Internal Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

⁴ Department of Gastroenclogy, Islamic Azad University of Najaf Abad, Isfahan, Iran

⁵ Department of General Physician, Isfahan University of Medical Sciences,Isfahan, Iran

Abstract

Background: Colorectal cancer (CRC) (adenomatous, adenocarcinoma) is one of the major causes of mortality and morbidity in human societies. Considering the importance of cyclooxygenase-2 (COX-2) expression in the incidence of CRC, in this study, the rate of COX-2 gene expression on polyps and CRCs were addressed.
Materials and Methods: This is a cross-sectional descriptive analytic study carried out on the blocks of sampled tissue of adenomatous and colorectal adenocarcinoma polyps on 68 patients referred to Digestive Clinic in Isfahan Shariati Hospital in 2013. Patients were divided into two groups of polyps (n = 52) and cancer (n = 16). Given the presence of CRC or polyps by colonoscopy, samples were sent to the laboratory to measure the rate of COX-2 gene expression using immunohistochemistry.
Results: In polyp group, 41 individuals (78.8%) had two or <2 polyps, 24 cases (46.2%) had a tubular polyp, and about a third of all patients had a big polyp. The most frequency of the polyp site was related to sigmoid with 19 cases (36.54%), in cancer group, it was related to the rectum with 9 cases (56.25%) that there was no significant difference between two groups (P < 0.05). The overall prevalence of COX-2 expression was positive in 51 cases (75%) and negative in 17 cases (25%). COX-2 gene expression was separately observed in 38 individuals (73.10%) in the polyp group and in 13 cases (81.25%) in the cancer group, and no significant difference was found (P > 0.05).
Conclusion: There is no relationship between COX-2 gene expression and the surface of adenomatous and colorectal adenocarcinoma polyps.

Keywords

References

1.	Boyle P, Langman JS. ABC of colorectal cancer: Epidemiology. BMJ 2000;321:805-8. [PUBMED]
2.	Parkin DM. Global cancer in the year 2009. Lancet Oncol 2010; 2:533-43.
3.	Alteri R, Kramer J, Simpson S. Colorectal Cancer Facts and Figures 2014-2016. Atlanta: American Cancer Society, 2014. p. 1-30.
4.	National Center Institute. A Snapshot of Colorectal Center; 2005. Available from: http://www.planning Cancer.gov/disease/ColorectaSnapshot.pdf. [Last accessed on 2013 Dec 15].
5.	Beahrs OH. Colorectal cancer staging as a prognostic feature. Cancer 1982;50 11 Suppl: 2615-7.
6.	Wiggers T, Arends JW, Volovics A. Regression analysis of prognostic factors in colorectal cancer after curative resections. Dis Colon Rectum 1988;31:33-41.
7.	Hannisdal E, Thorsen G. Regression analyses of prognostic factors in colorectal cancer. J Surg Oncol 1988;37:109-12.
8.	Gurpinar E, Grizzle WE, Piazza GA. COX-Independent mechanisms of cancer chemoprevention by anti-inflammatory drugs. Front Oncol 2013;3:181.
9.	Moran EM. Epidemiological and clinical aspects of nonsteroidal anti-inflammatory drugs and cancer risks. J Environ Pathol Toxicol Oncol 2002;21:193-201.
10.	Ogata Y, Torigoe S, Matono K, Sasatomi T, Ishibashi N, Shida S, et al. Prognostic factors after potentially curative resection in stage II or III colon cancer. Kurume Med J 2005;52:67-71.
11.	Liang JL, Wan DS, Pan ZZ, Zhou ZW, Chen G, Li LR, et al. Multivariate regression analysis of recurrence following curative surgery for colorectal cancer. Ai Zheng 2004;23:564-7.
12.	Yamamoto Y, Takahashi K, Yasuno M, Sakoma T, Mori T. Clinicopathological characteristics of skipping lymph node metastases in patients with colorectal cancer. Jpn J Clin Oncol 1998;28:378-82.
13.	Hojo K, Koyama Y. Postoperative follow-up studies on cancer of the colon and rectum. Am J Surg 1982;143:293-3. [PUBMED]
14.	Andreasson K. Emerging roles of PGE2 receptors in models of neurological disease. Prostaglandins Other Lipid Mediat 2010;91:104-12.
15.	Asero R, Quaratino D. Cutaneous hypersensitivity to multiple NSAIDs: Never take tolerance to selective COX-2 inhibitors (COXIBs) for granted! Eur Ann Allergy Clin Immunol 2013;45:3-6.
16.	Jung HJ, Cho YW, Lim HW, Choi H, Ji DJ, Lim CJ. Anti-Inflammatory, antioxidant, anti-angiogenic and skin whitening activities of Phryma leptostachya var. Asiatica hara extract. Biomol Ther (Seoul) 2013;21:72-8.
17.	Yamac D, Celenkoglu G, Coskun U, Akyurek N, Akcali Z, Dursun A, et al. Prognostic importance of COX-2 expression in patients with colorectal cancer. Pathol Res Pract 2005;201:497-502.
18.	Lim SC, Lee TB, Choi CH, Ryu SY, Min YD, Kim KJ. Prognostic significance of cyclooxygenase-2 expression and nuclear p53 accumulation in patients with colorectal cancer. J Surg Oncol 2008;97:51-6.
19.	Zhan J, Liu JP, Zhu ZH, Yao HR, Chen CY. Relationship between COX-2 expression and clinicopathological features of colorectal cancers. Chin Med J (Engl) 2004;117:1151-4.
20.	Yoshinaga M, Taki K, Somada S, Sakiyama Y, Kubo N, Kaku T, et al. The expression of both peroxisome proliferator-activated receptor delta and cyclooxygenase-2 in tissues is associated with poor prognosis in colorectal cancer patients. Dig Dis Sci 2011;56:1194-200.
21.	Miladi-Abdennadher I, Abdelmaksoud-Dammak R, Ayed-Guerfali DB, Ayadi L, Khabir A, Amouri A, et al. Expression of COX-2 and E-cadherin in Tunisian patients with colorectal adenocarcinoma. Acta Histochem 2012;114:577-81.

Advanced Biomedical Research